SCHEMBL6501972

SCHEMBL6501972

c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4cnn[nH]4)cc23)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 9/20 0.70
CLK2 P49760 7/20 0.70
GSK3B P49841 2/20 0.70
GAK O14976 1/20 0.70
DYRK3 O43781 1/20 0.70
JAK2 O60674 1/20 0.70
PRKD3 O94806 1/20 0.70
MAP4K4 O95819 1/20 0.70
NQO2 P16083 1/20 0.70
CSNK2A2 P19784 1/20 0.70
FECH P22830 1/20 0.70
JAK1 P23458 1/20 0.70
TYK2 P29597 1/20 0.70
MAPK8 P45983 1/20 0.70
MAPK9 P45984 1/20 0.70
CSNK1A1 P48729 1/20 0.70
CSNK1D P48730 1/20 0.70
CSNK1E P49674 1/20 0.70
CLK1 P49759 1/20 0.70
JAK3 P52333 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6506876 0.91 DYRK1A (0.58) DYRK1ACLK2GSK3BGAKDYRK3
Cc-401 SCHEMBL4607855 0.83 CLK2 (0.72) DYRK1ACLK2GSK3BGAKDYRK3
Cc-401 SCHEMBL29357538 0.83 CLK2 (0.74) DYRK1ACLK2GSK3BGAKDYRK3
Cc-401 SCHEMBL30290855 0.82 CLK2 (1.00) DYRK1ACLK2GSK3BGAKDYRK3
SCHEMBL8253744 0.82 CLK2 (1.00) DYRK1ACLK2GSK3BGAKDYRK3
Cc-401 SCHEMBL4604749 0.82 CLK2 (1.00) DYRK1ACLK2GSK3BGAKDYRK3
Cc-401 SCHEMBL23924447 0.81 CLK2 (0.98) DYRK1ACLK2GSK3BGAKDYRK3
Cc-401 SCHEMBL29403560 0.81 CLK2 (0.98) DYRK1ACLK2GSK3BGAKDYRK3
Cc-401 SCHEMBL29249167 0.81 CLK2 (0.98) DYRK1ACLK2GSK3BGAKDYRK3
Cc-401 SCHEMBL30198024 0.81 CLK2 (0.98) DYRK1ACLK2GSK3BGAKDYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R DYRK1A 426/4885CLK2 398/4885GSK3B 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.